Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ulrich Trechsel is active.

Publication


Featured researches published by Ulrich Trechsel.


Biochemical and Biophysical Research Communications | 1992

N-terminal truncation of salmon calcitonin leads to calcitonin antagonists : structure activity relationship of N-terminally truncated salmon calcitonin fragments in vitro and in vivo

Jean H.M. Feyen; Francis Cardinaux; Rainer Gamse; Christian Bruns; Moïse Azria; Ulrich Trechsel

Structural requirements for binding to the bone calcitonin (CT) receptor and for CT bioactivity both in vitro and in vivo were assessed for a series of N-terminally truncated, N alpha-acetylated, fragments of salmon calcitonin (sCT). Sequential deletion of amino acid residues from the amino-terminus of [Ala7]sCT-(2-32) peptide amide first led to partial agonists and, upon deletion of residues 1 to 7, to a high affinity antagonist, N alpha-acetyl-sCT-(8-32)-NH2. The presence of two separate domains within the sCT sequence is proposed: (I) a binding domain comprising residues 9-32 and (II) an activation domain requiring residues 3 to 6. N alpha-acetyl-sCT-(8-32)-NH2, in several bioassays including plasminogen activator release from LLC-PK1 cells (pA2 = 7.31), cAMP production in UMR-106-06 cells (pA2 = 7.81) and in the fetal rat long bone resorption assay showed potent antagonistic properties.


American Journal of Nephrology | 1985

Evidence for a Particularly Severe Secondary Hyperparathyroidism in Analgesic Abuse Nephropathy

Philippe Jaeger; Peter Burckhardt; Jean-Pierre Wauters; Ulrich Trechsel; Jean-Philippe Bonjour

Ca metabolism was compared in two groups of patients with chronic interstitial nephritis: in 21 patients (analgesic abuse nephropathy (AAN) group), nephropathy was due to exposure for 5-50 years (mean 21.1) to phenacetin-containing analgesics, whereas in 21 other patients (controls) it was due to exposure for 1-80 years (mean 21.4; NS) to other causes. Patients were followed for 2.5 +/- 0.6 and 1.6 +/- 0.6 years, respectively (mean +/- SEM; NS). Blood Ca, P, protein, creatinine, alkaline phosphatase, parathyroid hormone (PTH), 25-hydroxyvitamin D (25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D) as well as arterial acid-base status and urinary excretion rate of Ca, P and creatinine were determined serially. Results were included only when P was maintained between 0.7 and 1.9 mmol/l. The range of creatinine levels studied was 95-1,600 mumol/l. No differences were found between the two groups with respect to creatinine clearance, blood P, protein, arterial pH and bicarbonate, and urinary excretion rates of Ca and P. Mean plasma Ca was significantly lower, and PTH was significantly higher in the AAN group than in the control group; mean plasma alkaline phosphatase activity was also significantly higher in the AAN group. In both groups Ca was negatively correlated with creatinine, but the slope of the regression line was steeper in the AAN group than in controls. The degree of hypocalcemia was related to the increase in plasma PTH and alkaline phosphatase, but not to the plasma level of 25(OH)D or 1,25(OH)2D.(ABSTRACT TRUNCATED AT 250 WORDS)


The New England Journal of Medicine | 2002

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

Ian R. Reid; Jacques P. Brown; Peter Burckhardt; Zebulun D. Horowitz; Peter C. Richardson; Ulrich Trechsel; A Widmer; Jean-Pierre Devogelaer; Jean-Marc Kaufman; Philippe Jaeger; Jean-Jacques Body; Maria Luisa Brandi; Johann Broell; Raffaele Di Micco; Andrea R. Genazzani; Dieter Felsenberg; Joachim Happ; Michael J. Hooper; Jochen Ittner; Georg Leb; Hans Mallmin; Timothy M. Murray; S. Ortolani; Alessandro Rubinacci; Maria Sääf; Göran Samsioe; L. Verbruggen; Pierre J. Meunier


Journal of Bone and Mineral Research | 2009

Interleukin-6 is produced by bone and modulated by parathyroid hormone

Jean H.M. Feyen; Franco E. di Padova; Ulrich Trechsel; Peter Elford


Osteoporosis International | 2007

Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.

Jean-Pierre Devogelaer; Jacques P. Brown; Peter Burckhardt; Pierre J. Meunier; Stefan Goemaere; Kurt Lippuner; Jean-Jacques Body; Göran Samsioe; Dieter Felsenberg; T. Fashola; Liuska Sanna; C.E. Ortmann; Ulrich Trechsel; Joel S. Krasnow; Erik Fink Eriksen; Patrick Garnero


Archive | 2001

Method of administering bisphosphonates

Zebulun D. Horowitz; Peter C. Richardson; Ulrich Trechsel


Arthritis Research & Therapy | 2006

First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]

Ralf H Wittenberg; Ernest Schell; Gerhard Krehan; Roland Maeumbaed; Hans Runge; Peter Schlüter; T. Fashola; Helen Thurston; Klaus J Burger; Ulrich Trechsel


Archive | 1989

Use of an interleukin-6 molecule in inhibiting bone resorption

Jean H.M. Feyen; Ulrich Trechsel


Archive | 2004

Use of cathepsin k inhibitors in severe bone loss diseases

Martin Missbach; Rainer Gamse; Ulrich Trechsel


Osteoporosis International | 2006

Zoledronic acid safety and efficacy over 5 years in postmenopausal osteoporosis

Jean-Pierre Devogelaer; Peter Burckhardt; Pierre J. Meunier; Jean-Marc Kaufman; Kurt Lippuner; Jean-Jacques Body; Göran Samsioe; Dieter Felsenberg; Jacques P. Brown; Patrick Garnero; L. Sanna; C.E. Ortmann; Joel S. Krasnow; Erik Fink Eriksen; T. F. Fashola; Ulrich Trechsel

Collaboration


Dive into the Ulrich Trechsel's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jean-Jacques Body

Université libre de Bruxelles

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge